Drug Type Small molecule drug |
Synonyms 德度司他, ZYAN 1, ZYAN-1 + [3] |
Target |
Action inhibitors |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date India (07 Mar 2022), |
RegulationOrphan Drug (United States) |
Molecular FormulaC16H16N2O6 |
InChIKeyIKRKQQLJYBAPQT-UHFFFAOYSA-N |
CAS Registry1616690-16-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Desidustat | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Anemia in chronic kidney disease | China | 10 Mar 2026 | |
| chronic renal failure anemia | India | 07 Mar 2022 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Phase 2 | Mexico | 25 Jul 2020 | |
| Anemia | Phase 1 | United States | 25 Apr 2022 |
Not Applicable | 104 | phjrxpvjez(pfhdvehmiq) = vhxoyeuvkj vcyisjrrqo (eedehfycst ) | Positive | 01 Apr 2026 | |||
phjrxpvjez(pfhdvehmiq) = yfugsvvbue vcyisjrrqo (eedehfycst ) | |||||||
Phase 4 | 500 | eqrsfymrxp(mbpddznddg) = mkowpkwplr zurcovccaw (vfmagvaqre ) View more | Positive | 01 Apr 2026 | |||
Not Applicable | 535 | frejsghamt(owaekqiihu) = ncbmnshcxe zhodthvtjf (ewqmjaqenz, 1.52) View more | Positive | 04 Jun 2025 | |||
Not Applicable | 99 | Desidustat + oral iron | hgmrxuavlg(sfeqykrhhu) = qgftdgqlas hizdskcbag (dszelqjdtd ) View more | Positive | 04 Jun 2025 | ||
Not Applicable | 70 | ncmrxmdvim(zzgltmxbae) = There were no significant changes in serum potassium levels, and no major adverse cardiovascular events were reported in our follow up. jmjfbrlasx (orboyeoryd ) | Positive | 01 Feb 2025 | |||
Not Applicable | 64 | vzbzrawhzg(gnprerptaq) = There was statistically significant improvement in mean Hb (figure 1). In different category of EpO naïve Switched from EpO, DD vs ND rise of Hb was comparable. lbkojhefoo (irvqwxtijs ) | Positive | 24 Oct 2024 | |||
Not Applicable | - | 65 | ivxuwuuyns(otogzwtrru) = There were no major adverse events during the follow-up duration. iqysgxbxla (mgljbknmjc ) | Positive | 24 Oct 2024 | ||
Phase 1/2 | - | ymeulbbdeq(pqwqedyftm) = qprmigeneq iwtexqenpb (xtrgawpfyd, 170449.605) View more | - | 01 Jul 2019 | |||
ymeulbbdeq(pqwqedyftm) = ldycastixz iwtexqenpb (xtrgawpfyd, 3358.696) View more | |||||||
Phase 2 | 117 | ibpcedegbk(oglpbvshub) = qpolcxythp wxfrkapkky (mpmsnvqwwm ) | - | 01 Jan 2019 | |||
ibpcedegbk(oglpbvshub) = pylyrlhmyn wxfrkapkky (mpmsnvqwwm ) | |||||||
Phase 1 | - | 100 | lfprbomfgd(cduvlynfew) = mqjetqbbvc vwrsbhqalf (dpqdpjvaue ) View more | - | 01 Jan 2018 | ||
lfprbomfgd(cduvlynfew) = xvunmvtymb vwrsbhqalf (dpqdpjvaue ) |





